CA2816999A1 - Compositions and methods for nanopolymer-based nucleic acid delivery - Google Patents

Compositions and methods for nanopolymer-based nucleic acid delivery Download PDF

Info

Publication number
CA2816999A1
CA2816999A1 CA2816999A CA2816999A CA2816999A1 CA 2816999 A1 CA2816999 A1 CA 2816999A1 CA 2816999 A CA2816999 A CA 2816999A CA 2816999 A CA2816999 A CA 2816999A CA 2816999 A1 CA2816999 A1 CA 2816999A1
Authority
CA
Canada
Prior art keywords
nucleic acid
methods
compositions
nanopolymer
acid delivery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2816999A
Other languages
English (en)
French (fr)
Inventor
John N. Vournakis
Marina V. Demcheva
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Marine Polymer Technologies Inc
Original Assignee
Marine Polymer Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Marine Polymer Technologies Inc filed Critical Marine Polymer Technologies Inc
Publication of CA2816999A1 publication Critical patent/CA2816999A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CA2816999A 2010-11-06 2011-11-07 Compositions and methods for nanopolymer-based nucleic acid delivery Abandoned CA2816999A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US41086310P 2010-11-06 2010-11-06
US61/410,863 2010-11-06
US41135810P 2010-11-08 2010-11-08
US61/411,358 2010-11-08
PCT/US2011/059558 WO2012061803A2 (en) 2010-11-06 2011-11-07 Compositions and methods for nanopolymer-based nucleic acid delivery

Publications (1)

Publication Number Publication Date
CA2816999A1 true CA2816999A1 (en) 2012-05-10

Family

ID=46025153

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2816999A Abandoned CA2816999A1 (en) 2010-11-06 2011-11-07 Compositions and methods for nanopolymer-based nucleic acid delivery

Country Status (10)

Country Link
US (3) US20130287853A1 (enExample)
EP (1) EP2635261B1 (enExample)
JP (2) JP6029591B2 (enExample)
CN (2) CN103282024A (enExample)
AU (3) AU2013203247A1 (enExample)
CA (1) CA2816999A1 (enExample)
ES (1) ES2763432T3 (enExample)
IL (1) IL226170B (enExample)
MX (1) MX358050B (enExample)
WO (1) WO2012061803A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2918452T3 (es) 2007-02-19 2022-07-15 Marine Polymer Tech Inc Composiciones hemostáticas y regímenes terapéuticos
NZ703163A (en) 2010-04-15 2016-06-24 Marinepolymer Tech Inc Anti-bacterial applications of poly-n-acetylglucosamine nanofibers
CN103282024A (zh) * 2010-11-06 2013-09-04 海洋聚合物技术公司 用于纳米聚合物基核酸递送的组合物和方法
EP2696680B1 (en) 2011-04-15 2018-11-28 Marine Polymer Technologies, Inc. Treatment of hsv infections with poly-n-acetyl glucosamine nanofibers
CA2968160C (en) * 2016-05-31 2024-01-02 Sachiko Sato Use of n-acetylglucosamine and derivatives thereof to treat muscle disorders
EP3693024A1 (en) * 2019-02-05 2020-08-12 Altona Diagnostics GmbH Control for nucleic acid preparation and/or detection methods
IT202200004574A1 (it) * 2022-03-10 2023-09-10 Sergio Ammendola Nanoparticelle di N-acetilglucosammina e loro applicazioni

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
GB0126923D0 (en) * 2001-11-09 2002-01-02 Procter & Gamble Chitosan compositions
US7780873B2 (en) * 2004-02-23 2010-08-24 Texas A&M University System Bioactive complexes compositions and methods of use thereof
JP2005281239A (ja) * 2004-03-30 2005-10-13 Nippon Zeon Co Ltd 鶏用ｄｎａワクチン
US20060105049A1 (en) * 2004-11-12 2006-05-18 Valorisation Recherche Hscm & Universite De Montreal Folic acid-chitosan-DNA nanoparticles
ATE539079T1 (de) 2006-03-23 2012-01-15 Novartis Ag Imidazochinoxalinverbindungen als immunmodulatoren
CA2646891A1 (en) 2006-03-23 2007-09-27 Novartis Ag Immunopotentiating compounds
WO2008039390A2 (en) * 2006-09-22 2008-04-03 Government Of The Usa., Dept. Of Health & Human Services Compositions and methods for chitosan enhanced immune response
KR100882611B1 (ko) * 2006-11-14 2009-02-12 주식회사 키토라이프 표적 리간드로서 폴릭산이 도입된 유전자 전달체용저분자량 수용성 키토산 나노입자 및 이의 제조방법
WO2008094659A2 (en) * 2007-01-31 2008-08-07 Allergan, Inc. Novel biomaterials for ocular drug delivery and a method for making and using same
US20100086613A1 (en) * 2008-10-03 2010-04-08 Chang-Jer Wu Chitosan vehicle and method for making same
US20100105139A1 (en) * 2008-10-27 2010-04-29 Remco Alexander Spanjaard Ligand Targeted Nanocapsules for the delivery of RNAi and other Agents
CA2833415A1 (en) * 2010-05-10 2011-11-17 Corporation De L'ecole Polytechnique De Montreal Gene therapy for diabetes with chitosan-delivered plasmid encoding glucagon-like peptide 1
CN103282024A (zh) * 2010-11-06 2013-09-04 海洋聚合物技术公司 用于纳米聚合物基核酸递送的组合物和方法

Also Published As

Publication number Publication date
MX358050B (es) 2018-08-03
ES2763432T3 (es) 2020-05-28
CN103282024A (zh) 2013-09-04
IL226170B (en) 2018-11-29
US20130287853A1 (en) 2013-10-31
AU2013203247A1 (en) 2013-05-09
US20170128382A1 (en) 2017-05-11
EP2635261A2 (en) 2013-09-11
WO2012061803A3 (en) 2012-08-16
AU2016201640A1 (en) 2016-04-07
AU2011323078A1 (en) 2013-05-02
JP2014500250A (ja) 2014-01-09
JP6029591B2 (ja) 2016-11-24
WO2012061803A2 (en) 2012-05-10
CN108743562A (zh) 2018-11-06
JP2016164181A (ja) 2016-09-08
MX2013005016A (es) 2014-03-12
EP2635261A4 (en) 2014-09-17
US20230157971A1 (en) 2023-05-25
AU2011323078B2 (en) 2016-04-14
EP2635261B1 (en) 2019-10-23
IL226170A0 (en) 2013-07-31

Similar Documents

Publication Publication Date Title
MX358050B (es) Composiciones y métodos para la entrega de ácido nucleico a base de nanopolímeros.
MX342439B (es) Metodos para producir nanoparticulas polimericas y formulaciones de ingredientes activos.
HK1208161A1 (en) Pharmaceutical nanoparticles showing improved mucosal transport
NZ604063A (en) Compositions and methods for enhancing physiological performance and recovery time
WO2008089268A3 (en) Methods and compositions for treating conditions associated with infection and/or inflammation
WO2010087964A3 (en) Compositions for treatment and prevention of acne, methods of making the compositions, and methods of use thereof
WO2012047733A3 (en) Treatment of acne by conditioned media
WO2014004993A3 (en) Methods of reducing ldl-p
NZ603411A (en) Pazopanib compositions and their use in treating ocular diseases
WO2013006729A3 (en) Cannabinoid receptor binding agents, compositions and methods
WO2010075072A3 (en) Long circulating nanoparticles for sustained release of therapeutic agents
IN2014KN00996A (enExample)
WO2012000103A8 (en) Methods of targeting pten mutant diseases and compositions therefor
WO2014004861A3 (en) Methods of treating pediatric metabolic syndrome
WO2013041975A3 (en) Pyrethroid formulations
WO2012143499A3 (de) Neue binder-wirkstoff konjugate (adcs) und ihre verwendung
WO2012001074A3 (en) Pharmaceutical compositions comprising 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactate monohydrate
WO2012104275A3 (en) Nanoparticles delivery systems, preparation and uses thereof
WO2011129588A3 (ko) 경피흡수용 고분자-리포좀 나노복합체 조성물 및 그 제조방법
WO2013067199A3 (en) Subcutaneous delivery of polymer conjugates of therapeutic agents
WO2011069010A3 (en) Amantadine compositions and methods of use
GB201121288D0 (en) Functionalised silicon nanoparticles
NZ595904A (en) A novel formulation of meloxicam
PH12013500923A1 (en) Compositions of rotigotine, derivatives thereof, or pharmaceutically acceptable salts of rotigotine or its derivative
HK1200695A1 (en) Optimised subcutaneous therapeutic agents

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20171107